Ulcer. Other and unspecified malignant neoplasm of skin
Conditions
Interventions
Intervention 1: The intervention group includes oral capsule and topical solution of Sikaglocal. The patient receives one capsule daily for 2 weeks (14 capsules) and topical solution twice a day for 2
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who have undergone Mohs surgery due to skin cancer of the head and face Age should be in the range of 50 to 80 years. Completing the consent form to participate in the study
Exclusion criteria
Exclusion criteria: Surgery in an area of ??the body other than the head and face Skin cancer of a type other than SCC and BCC The presence of a specific underlying disease that directly leads to a disorder in wound healing, including scleroderma and morphea
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining the effect of oral and topical cikaglocal drug on wound healing in patients after Mohs surgery, where the wound healing score is given based on the Early Healing Index (EHI). Timepoint: In each group, the number of patients will be 12, and on days 0, 7, and 14, imaging of the patients' wounds will be done, and the duration of drug use is 14 days. Method of measurement: The wound healing score is based on the Early Healing Index (EHI), which evaluates wound healing using scores from 1 to 5: a wound with very poor healing receives a score of 1, while excellent healing receives a score of 5. slow. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Mohammadian
Esfahan University of Medical Sciences
Outcome results
None listed